InvestSMART

Actinogen Medical Limited (ASX: ACW) - Announcements

Current share price for ACW : $0.041 0.002 (4.65%)+

ASX company news and announcements for Actinogen Medical Limited (ACW) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Actinogen Medical Limited (ACW) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Actinogen Medical Limited (ACW), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Actinogen Medical Limited (ACW)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$159 ACW successfully completes $16.8m Placement and SPP 27 Feb 2026 9:33AM $0.042 $0.041 fallen by 2.38%
$159 Application for quotation of securities - ACW 26 Feb 2026 1:47PM $0.042 $0.041 fallen by 2.38%
$159 ACW HY26 results - XanaMIA pivotal Alzheimers trial progress 26 Feb 2026 10:27AM $0.041 $0.041 fallen by 0%
$159 Actinogen HY2025 financial report and Appendix 4D 26 Feb 2026 10:26AM $0.041 $0.041 fallen by 0%
$159 Letter to Shareholders, Notice of Meeting & Proxy Form 13 Feb 2026 2:02PM $0.041 $0.041 fallen by 0%
$159 Application for quotation of securities - ACW 12 Feb 2026 2:17PM $0.043 $0.041 fallen by 4.65%
$159 ACW receives further $1.9m FY2025 R&D rebate from ATO 11 Feb 2026 9:37AM $0.043 $0.041 fallen by 4.65%
$159 Letter to Eligible Shareholders 10 Feb 2026 9:23AM $0.044 $0.041 fallen by 6.82%
$159 Share Purchase Plan Booklet 10 Feb 2026 9:22AM $0.044 $0.041 fallen by 6.82%
$159 Cleansing Notice 9 Feb 2026 9:39AM $0.043 $0.041 fallen by 4.65%
$159 Application for quotation of securities - ACW 9 Feb 2026 9:35AM $0.043 $0.041 fallen by 4.65%
$159 Application for quotation of securities - ACW 5 Feb 2026 1:27PM $0.047 $0.041 fallen by 12.77%
$159 Proposed issue of securities - ACW 2 Feb 2026 9:57AM $0.045 $0.041 fallen by 8.89%
$159 Proposed issue of securities - ACW 2 Feb 2026 9:57AM $0.045 $0.041 fallen by 8.89%
$159 Proposed issue of securities - ACW 2 Feb 2026 9:57AM $0.045 $0.041 fallen by 8.89%
$159 ACW secures funding beyond XanaMIA AD trial final results 2 Feb 2026 9:56AM $0.045 $0.041 fallen by 8.89%
$159 ACW December 2025 quarterly activity report & Appendix 4C 30 Jan 2026 10:11AM $0.045 $0.041 fallen by 8.89%
$159 Continuation of Trading Halt 30 Jan 2026 9:52AM $0.045 $0.041 fallen by 8.89%
$159 ACW positive XanaMIA Interim Analysis outcome 30 Jan 2026 9:51AM $0.045 $0.041 fallen by 8.89%
$159 Trading Halt 29 Jan 2026 9:03AM $0.045 $0.041 fallen by 8.89%
$159 Actinogen secures $4.3m of non-dilutive R&D tax funding 27 Jan 2026 9:02AM $0.050 $0.041 fallen by 18%
$159 Application for quotation of securities - ACW 22 Jan 2026 3:16PM $0.050 $0.041 fallen by 18%
$159 Application for quotation of securities - ACW 15 Jan 2026 4:28PM $0.049 $0.041 fallen by 16.33%
$159 ACW at Sachs Neuroscience and JPM week in San Francisco 12 Jan 2026 9:11AM $0.059 $0.041 fallen by 30.51%
$159 Application for quotation of securities - ACW 8 Jan 2026 3:55PM $0.068 $0.041 fallen by 39.71%

76 - 100 of 916 results

Page 4 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.